imported>Bestem |
imported>Bestem |
| (6 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| == Therapie ==
| |
| <span style="color: black">Die Therapie greift den Stoffwechsel der Tachyzoiten an und ist gegen bradyzoitenhaltige Gewebezysten kaum wirksam.</span>
| |
|
| |
| <span style="font-size:10.5pt;line-height:107%;font-family:"Arial",sans-serif;
| |
| mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:
| |
| DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA">Therapieindikationen bestehen bei aktiver Infektion/Reaktivierung des Immunsupprimierten, okulärer Toxoplasmose, Erstinfektion in der Schwangerschaft und konnataler Infektion. Eine unkomplizierte Erstinfektion beim nicht-schwangeren Immunkompetenten bedarf keiner Therapie.</span>
| |
|
| |
| === 5.1 Kalkulierte Therapie ===
| |
| {| class="wikitable sortable bs-exportable filterable MsoTableGrid" border="1" cellspacing="0" cellpadding="0" align="left" width="723" style="border-collapse:collapse;mso-table-layout-alt:fixed;
| |
| border:none;mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:1184;
| |
| mso-table-lspace:7.05pt;margin-left:4.8pt;mso-table-rspace:7.05pt;margin-right:
| |
| 4.8pt;mso-table-anchor-vertical:paragraph;mso-table-anchor-horizontal:margin;
| |
| mso-table-left:center;mso-table-top:-16.95pt;mso-padding-alt:0cm 5.4pt 0cm 5.4pt"
| |
| |+
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:117.7pt;" width="157" |<span style="font-size:8.0pt;mso-no-proof:yes">'''Klinische Situation'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:80.9pt;" width="108" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Präferenz'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:78.3pt;" width="104" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Substanz'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:82.4pt;" width="110" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Dosierung'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:44.85pt;" width="60" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Dauer'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:65.55pt;" width="87" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Anpassungen'''</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-left-color:#acacac;border-right-color:#acacac;border-top-color:#acacac;border-bottom-color:#acacac;width:72.45pt;" width="97" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">'''Kommentar'''</span>
| |
| |- style="height:78.55ptpx;"
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-top-color:#acacac;width:78.3pt;" width="104" valign="top" |[https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Pyrimethamin <span style="color: windowtext">Pyrimethamin</span>]
| |
|
| |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">dann</span>
| |
|
| |
| [https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Pyrimethamin <span style="color: windowtext">Pyrimethamin</span>]
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;border-top-color:#acacac;width:82.4pt;" width="110" valign="top" |<span style="font-size:8.0pt;line-height:300%;font-family:"Calibri",sans-serif;
| |
| mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
| |
| Arial;mso-bidi-theme-font:minor-bidi;mso-no-proof:yes">1 x 200 mg p.o.</span>
| |
|
| |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">< 60 kg 1 x 50 mg p.o.</span>
| |
|
| |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">≥ 60 kg 1 x 75 mg p.o.</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:32.3ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |+
| |
|
| |
| Calciumfolinat
| |
|
| |
|
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" |1 x 15 mg p.o.
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:16.0ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Wenn <span style="mso-spacerun:yes"> </span>Serologie<sup>2</sup>, MRT, CT mit Kontrastmittel (Liquor- PCR)<sup>3</sup>, Histologie : Therapie der 1. Wahl</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" valign="top" |+
| |
|
| |
|
| | Die Therapie greift den Stoffwechsel der Tachyzoiten an und ist gegen bradyzoitenhaltige Gewebezysten kaum wirksam. |
|
| |
|
| | Therapieindikationen bestehen bei aktiver Infektion/Reaktivierung des Immunsupprimierten, okulärer Toxoplasmose, Erstinfektion in der Schwangerschaft und konnataler Infektion. Eine unkomplizierte Erstinfektion bei nicht-schwangeren und immunkompetenten Menschen bedarf regelhaft keiner Therapie. |
| | <br /> |
|
| |
|
| [https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Sulfadiazin Sulfadiazin]
| | {{DGI:Zerebrale Toxoplasmose/Kalkulierte_Therapie}} |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" |4 x 1 - 1,5 g p.o.
| | {{DGI:Zerebrale Toxoplasmose/Erregerspezifische Therapie}} |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="color: #333333">Therapie in angegebener Dosis für ca. 6 Wochen</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="color: #333333">Blutbildkontrollen aufgrund Risiko der Myelosuppression; Vorsicht bei Nieren- oder Leberfunktionsstörung; Sulfadiazin bei schwerer Nieren- oder Leberfunktionsstörung kontraindiziert;Kristallurie mit akutem Nierenversagen möglich</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="color: #333333">Im Anschluss an Therapie in voller Dosis Erhaltungstherapie in halber Dosierung für mind. 3 Monate (in Abhängigkeit von Bildgebung und CD4+ Zellzahl)</span>
| |
| |- style="height:19.4ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:80.9pt;" width="108" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Wenn <span style="mso-spacerun:yes"> </span>Liquorprotein > 1 g/dl oder Chorioretinitis: Therapie der 1. Wahl</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">s.o. +</span>
| |
| | |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Prednison</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="top" |2 x 500 µg/kg p.o.
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:44.85pt;" width="60" valign="bottom" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:65.55pt;" width="87" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:72.45pt;" width="97" |
| |
| |- style="height:28.05ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |[https://abbuch.uk-koeln.de/index.php/Antibiotika#Clindamycin <span style="color: windowtext">Clindamycin</span>]
| |
| | |
| <span style="font-size:8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
| |
| minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
| |
| mso-bidi-theme-font:minor-bidi;mso-no-proof:yes">oder</span>
| |
| | |
| [https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Atovaquon <span style="color: windowtext">Atovaquon</span>]
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="top" |<span style="font-size:8.0pt;line-height:200%;font-family:"Calibri",sans-serif;
| |
| mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:
| |
| Arial;mso-bidi-theme-font:minor-bidi;mso-no-proof:yes">2 x 1,2 g p.o./i.v.</span>
| |
| | |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">2 x 1,5 g p.o.</span>
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:28.75ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">mit einer Mahlzeit jeweils</span>
| |
| | |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">+</span>
| |
| | |
| [https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Pyrimethamin <span style="color: windowtext">Pyrimethamin</span>]
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="bottom" |1 x 200 mg p.o.
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:29.4ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |dann
| |
| | |
| [https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Pyrimethamin Pyrimethamin]
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="bottom" |< 60 kg 1 x 50 mg p.o.
| |
| | |
| ≥ 60 kg 1 x 75 mg p.o.
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:1.45ptpx;"
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |[https://abbuch.uk-koeln.de/index.php/Therapie_der_HIV-Infektion <span style="color: windowtext">HIV-Infektion</span>] <span style="font-size:8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:
| |
| minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;
| |
| mso-bidi-theme-font:minor-bidi;mso-no-proof:yes">(CD4 Zellzahl < 100/µl) ohne effektive Prophylaxe, allogene Stammzell- und Organtransplantation</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Allergie/</span>
| |
| | |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Unverträglichkeit</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |+
| |
| | |
| Calciumfolinat
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="bottom" |1 x 15 mg p.o.
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="color: #333333">Blutbildkontrollen aufgrund Risiko der Myelosuppression; Vorsicht bei Nieren- oder Leberfunktionsstörung</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:24.35ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |[https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Pyrimethamin <span style="color: windowtext">Pyrimethamin</span>]
| |
| | |
| <span style="font-size:8.0pt;mso-fareast-font-family:"Times New Roman";mso-fareast-language:
| |
| DE;mso-no-proof:yes">+</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" |<span style="font-size:
| |
| 8.0pt;mso-no-proof:yes">1 </span><span style="font-size:8.0pt;font-family:
| |
| "Calibri",sans-serif;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:
| |
| minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:minor-bidi;
| |
| mso-no-proof:yes">x 1 mg/kgKG p.o.</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:44.85pt;" width="60" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:12.8ptpx;"
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" valign="bottom" |[https://abbuch.uk-koeln.de/index.php/Antiparasit%C3%A4re_Substanzen#Sulfadiazin <span style="color: windowtext">Sulfadiazin</span>]
| |
| | |
| <span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">+</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="top" |100 mg /kgKG p.o. 2 ED
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:44.85pt;" width="60" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| |- style="height:12.8ptpx;"
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">konnatal erworben, symptomatisch</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:78.3pt;" width="104" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">Calciumfolinat</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:82.4pt;" width="110" valign="bottom" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">10 mg/Woche p.o. 2 ED</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;width:44.85pt;" width="60" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-no-proof:yes">für 12 Monate</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="color: #333333">Spiegelbestimmung, v.a. bei Hinweis auf Myelosuppression; Vorsicht bei Nieren- oder Leberfunktionsstörung Sulfadiazin bei schwerer Nieren- oder Leberfunktionsstörung kontraindiziert; Kristallurie mit akutem Nierenversagen möglich</span>
| |
| | style="vertical-align:middle;text-align:left;border-left-width:1px;border-right-width:1px;border-top-width:1px;border-bottom-width:1px;" |<span style="font-size:
| |
| 8.0pt;font-family:"Calibri",sans-serif;mso-ascii-theme-font:minor-latin;
| |
| mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;
| |
| mso-hansi-theme-font:minor-latin;mso-bidi-font-family:Arial;mso-bidi-theme-font:
| |
| minor-bidi;mso-fareast-language:EN-US;mso-no-proof:yes">Bei asymptomatischen Neugeborenen (nur Labornachweis der Infektion), ggf. Kurzzeittherapie über 3-6 Monate erwägen</span>
| |
| |}
| |
| <br />
| |
